Indication

ZIRGAN® is an antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older.

Important Safety Information
  • ZIRGAN® is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN®.
  • Do not allow the tip of the container to touch any surface, as this may contaminate the ointment.
  • If pain develops or if redness, itching, or inflammation becomes aggravated, the patient should be advised to consult a physician.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Please see full Prescribing Information for ZIRGAN® or Click here for full Prescribing Information for ZIRGAN®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.1-800-FDA-1088.

THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.

Please choose an option below: